ASCO25: J&J’s trispecific antibody shows 100% response in Phase I multiple myeloma study

First-in-human data for the trispecific antibody “suggest a paradigm shift” for the relapsed/refractory multiple myeloma space.

Jun 5, 2025 - 06:00
ASCO25: J&J’s trispecific antibody shows 100% response in Phase I multiple myeloma study
First-in-human data for the trispecific antibody “suggest a paradigm shift” for the relapsed/refractory multiple myeloma space.

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow